Company intelligence / Profile preview

MCM6 Therapeutics

Lexington, Massachusetts, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

No clinical results or pipeline details are publicly available. The company's name suggests a focus on targeting the MCM6 protein, which has been identified in academic research as a promising target for cancer therapy due to its role in tumor growth and metastasis.

However, there are no direct reports of clinical-stage programs or published trial outcomes associated with this company.

Therapeutic areas: Oncology
Modalities: Not specified in public sources; likely small molecules or targeted therapies based on the name and typical biotech focus, but this cannot be confirmed from available data.
Industry: Biotech

Drug pipeline

1 asset

purpureaside C

Pre-clinical

Indications: Gastric cancer

Partnerships

None disclosed

Beyond the preview

Go deeper on MCM6 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCM6 Therapeutics.

Explore the full profile